Indonesia Next Generation Sequencing Ngs Services Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

Indonesia Next Generation Sequencing (NGS) Services Market Overview

• The Indonesia Next Generation Sequencing (NGS) Services Market is valued at USD 9 billion, based on a five-year historical analysis. This growth is primarily driven by advancements in genomic research, increasing demand for personalized medicine, and the rising prevalence of genetic disorders. The integration of NGS technology in clinical diagnostics and research has significantly contributed to the market's expansion, as healthcare providers seek more efficient and accurate methods for disease detection and treatment. The market is further propelled by the falling cost of sequencing, wider accessibility, and the growing adoption of high-throughput sequencing platforms, which enable more precise and rapid genetic analysis .
• Key cities such asJakarta, Surabaya, and Bandungdominate the NGS services market due to their robust healthcare infrastructure, presence of research institutions, and access to advanced technologies. Jakarta, being the capital, serves as a hub for medical research and innovation, while Surabaya and Bandung are known for their academic institutions that foster research and development in genomics. Java, where these cities are located, accounts for a substantial share of the Indonesian NGS market, reflecting the concentration of healthcare resources and genomic research activity .
• In 2022, the Indonesian government launched theNational Genome Centerunder the Ministry of Health, in collaboration with Illumina Inc. This regulation, titled “Peraturan Menteri Kesehatan Republik Indonesia Nomor 24 Tahun 2022 tentang Penyelenggaraan Pusat Genom Nasional” (Regulation of the Minister of Health of the Republic of Indonesia Number 24 of 2022 concerning the Operation of the National Genome Center), establishes provisions for funding, infrastructure development, and support for NGS initiatives. It encourages collaboration between public and private sectors, mandates compliance with national standards for genomic research, and sets operational thresholds for clinical and research sequencing activities. The government aims to enhance the country's capabilities in genomics, thereby improving healthcare outcomes and fostering innovation in the biotechnology sector .

Indonesia Next Generation Sequencing (NGS) Services Market Segmentation

By Type:The NGS services market can be segmented into various types, including Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing, RNA Sequencing, and Others. Whole Genome Sequencing is gaining traction due to its comprehensive nature, allowing for the analysis of entire genomes, which is crucial for understanding complex diseases. Targeted Sequencing is also popular as it focuses on specific areas of interest, making it cost-effective and efficient for clinical applications. RNA Sequencing is increasingly utilized for gene expression analysis, further driving the market.

By End-User:The end-users of NGS services include Hospitals, Research Laboratories, Pharmaceutical Companies, Academic Institutions, and Others. Hospitals are the leading end-users, as they increasingly adopt NGS for diagnostics and personalized treatment plans. Research Laboratories follow closely, utilizing NGS for various studies, including cancer research and genetic disorder investigations. Pharmaceutical Companies leverage NGS for drug development and biomarker discovery, while Academic Institutions focus on research and education in genomics.

Indonesia Next Generation Sequencing (NGS) Services Market Competitive Landscape

The Indonesia Next Generation Sequencing (NGS) Services Market is characterized by a dynamic mix of regional and international players. Leading participants such as PT. Genetika Science, PT. Bio Farma, Eijkman Institute for Molecular Biology, PT. BGI Genomics Indonesia, PT. Novogene Indonesia, PT. Illumina Indonesia, PT. Agilent Technologies Indonesia, PT. Thermo Fisher Scientific Indonesia, PT. QIAGEN Indonesia, PT. Roche Indonesia, PT. PerkinElmer Indonesia, PT. Merck Indonesia, PT. GATC Biotech Indonesia, PT. Genomatix Indonesia, PT. 23andMe Indonesia contribute to innovation, geographic expansion, and service delivery in this space.

Indonesia Next Generation Sequencing (NGS) Services Market Industry Analysis

Growth Drivers

• Increasing Demand for Personalized Medicine:The Indonesian healthcare sector is witnessing a surge in personalized medicine, driven by a growing population of over 280 million. In future, the market for personalized medicine is projected to reach IDR 10 trillion, reflecting a 15% increase from the previous year. This demand is fueled by advancements in NGS technology, enabling tailored treatments for various diseases, particularly cancer and genetic disorders, thus enhancing patient outcomes and driving market growth.
• Advancements in Genomic Research:Indonesia's investment in genomic research has increased significantly, with government funding reaching IDR 1.5 trillion in future. This funding supports various research initiatives, including the Human Genome Project and local biobanks. The establishment of research institutions, such as the Eijkman Institute, has further accelerated genomic studies, leading to breakthroughs in understanding genetic diseases and fostering the adoption of NGS services across the healthcare landscape.
• Rising Prevalence of Genetic Disorders:The prevalence of genetic disorders in Indonesia is estimated at 1 in 1,000 births, translating to approximately 280,000 cases annually. This alarming statistic has prompted healthcare providers to seek advanced diagnostic tools, including NGS services. The increasing awareness of genetic testing's importance in early diagnosis and treatment is expected to drive demand, leading to a projected growth in NGS services utilization by 20% in future.

Market Challenges

• High Costs of NGS Technology:The initial investment for NGS technology remains a significant barrier, with costs averaging IDR 500 million per sequencing machine. This high capital requirement limits accessibility for smaller healthcare facilities and research institutions. As a result, only 30% of hospitals in Indonesia currently offer NGS services, hindering widespread adoption and limiting the potential market growth in the short term.
• Limited Awareness Among Healthcare Providers:Despite the benefits of NGS, awareness among healthcare providers in Indonesia is still low, with only 40% of practitioners familiar with its applications. This lack of knowledge leads to underutilization of NGS services, particularly in rural areas where healthcare resources are scarce. Educational initiatives and training programs are essential to bridge this gap and promote the integration of NGS into standard medical practice.

Indonesia Next Generation Sequencing (NGS) Services Market Future Outlook

The future of Indonesia's NGS services market appears promising, driven by technological advancements and increasing healthcare investments. In future, the government aims to enhance healthcare infrastructure, allocating IDR 5 trillion for biotechnology initiatives. Additionally, the integration of artificial intelligence in genomic data analysis is expected to streamline processes and improve accuracy. As awareness grows and costs decrease, the adoption of NGS services is likely to expand, fostering innovation and improving patient care across the nation.

Market Opportunities

• Expansion of Research Institutions:The establishment of new research institutions in Indonesia is projected to increase by 25% in future, providing a robust platform for NGS services. This growth will facilitate collaborations with international biotech firms, enhancing research capabilities and driving innovation in genetic testing and personalized medicine.
• Development of Cost-Effective NGS Solutions:The demand for affordable NGS solutions is rising, with a projected market for low-cost sequencing technologies expected to reach IDR 2 trillion by future. Companies focusing on developing these solutions can tap into a growing customer base, particularly among smaller healthcare providers and research institutions seeking to adopt NGS services.